Preservation of Ovarian Function After Hematopoietic Cell Transplant

Stopped early · Phase 2

Conditions studied: Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders

In brief

Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.

Key facts

Study ID
NCT01343368
Run by
Masonic Cancer Center, University of Minnesota
People needed
19
Starts
2011-07-01
Expected to finish
2015-04-01
Last updated by the study team
2017-12-05

Who can join

Age: 50 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.